Sanuwave Health (NASDAQ:SNWV) Posts Earnings Results, Misses Estimates By $0.17 EPS

Sanuwave Health (NASDAQ:SNWV) released its quarterly earnings results on Tuesday. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.17), FiscalAI reports. Sanuwave Health had a net margin of 32.38% and a return on equity of 1,728.10%. The firm had revenue of $8.58 million for the quarter, compared to analysts’ expectations of $13.75 million.

Sanuwave Health Price Performance

Sanuwave Health stock traded up $0.03 during mid-day trading on Tuesday, hitting $1.88. 92,741 shares of the company traded hands, compared to its average volume of 113,441. Sanuwave Health has a one year low of $1.75 and a one year high of $36.20. The stock has a market cap of $16.17 million, a price-to-earnings ratio of 7.83 and a beta of 1.47. The company has a debt-to-equity ratio of 4.87, a quick ratio of 0.89 and a current ratio of 1.28. The stock has a fifty day moving average price of $4.73 and a 200-day moving average price of $12.91.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Sanuwave Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, November 4th. One analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Reduce” and an average price target of $47.00.

Sanuwave Health Company Profile

SANUWAVE Health, Inc. is a medical technology company focused on regenerative medicine and advanced wound-care solutions. The company develops and commercializes noninvasive devices that use extracorporeal shock wave technology to stimulate biological responses in damaged or difficult-to-heal tissue. Its principal product is the dermaPACE system, which is designed to deliver acoustic shock waves to wound areas, including chronic diabetic foot ulcers. SANUWAVE has also pursued additional applications for its platform in areas such as orthopedic and soft-tissue healing, although the availability and regulatory status of specific products may vary by geography.